Xbrane to Initiate New Biosimilar Development Program Annually

 Xbrane to Initiate New Biosimilar Development Program Annually


  • Xbrane to initiate a new biosimilar development program annually and planning to generate positive operating cash flow monthly on the back of expected Xlucane net-income by late 2023/early 2024
  • Xlucane (biosimilar, ranibizumab) referencing Lucentis is currently in the P-III trial with expected results in mid-2021, regulatory submissions are underway in the EU in Q3 & the US in Q4’21. If approved, Xlucane will be launched across the EU and the US
  • The company has set the foundation for growth through establishing a new biotech lab at Campus Solna with a team of 50 professionals to take biosimilars from cell-line to approval and strengthen its high yield/low-cost platform technology

Click here to­ read full press release/ article | Ref: Xbrane | Image: Xbrane

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post